Drug Patents owned by Vertex Pharms

1. List of Incivek drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms
May, 2028

(5 years from now)

Drugs and Companies using TELAPREVIR ingredient

Market Authorisation Date: 23 May, 2011

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Kalydeco drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9670163 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 31 January, 2012

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; Method of treating cystic fibrosis; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic